Tag: anti-BCMA

Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs).  Kelonia’s iGPS platform…

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board — Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development — BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today…

PRESS RELEASE Published May 5, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in the Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor…

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.1 The FDA has assigned…

PRESS RELEASE Published April 17, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route…

U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma Bristol Myers Squibb’s supplemental New Drug Application for Abecma has also been…

Caribou Biosciences is a biopharma company that has proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which allows for the creation of genome-edited cell therapies. One of the products of this technology, CB-011, was provided Fast Track designation by the US Food and Drug Administration (FDA). The treatment candidate is being evaluated…

PRESS RELEASE Published March 27, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

PRESS RELEASE Published March 15, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023,” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including CAR-T clinical trial and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment…

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first and only CAR T cell therapy to demonstrate superiority over standard regimens in…

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study Details Category: DNA RNA and Cells Published on Saturday, 11 February 2023 09:46 Hits: 80…

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first and only CAR T cell therapy to demonstrate superiority over standard regimens in…

MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides a fourth quarter 2022 business update and an outlook for 2023. Michel Lussier, interim Chief Executive Officer…

PRESS RELEASE Published February 2, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext &…

This article was originally published here Cancer Gene Ther. 2021 Sep 1. doi: 10.1038/s41417-021-00365-x. Online ahead of print. ABSTRACT The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone…

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added another $40 million after its financial underwriters opted to buy…